Pharma News - Chemdiv

Pfizer sues departing employee it says stole COVID-19 vaccine secrets

Pfizer Inc has sued a longtime employee for allegedly stealing "scores" of confidential documents, including some related to its COVID-19 vaccine, as she prepared to jump to a competitor. ...

FDA Grants Fast Track Status to Arfolitixorin for Metastatic Colorectal Cancer

The FDA has granted a fast track designation to arfolitixorin as a potential therapeutic option for patients with metastatic colorectal cancer (mCRC), according to an announcement from Isofol Medical ...

Takeda's post-transplant CMV drug Livtencity, shouldering $800M in sales expectations, scores FDA nod

Transplant patients who experience a potentially deadly viral infection that doesn’t respond to existing treatments have a new FDA-approved treatment option.

Aadi clinches first FDA nod for ultrarare sarcoma drug Fyarro

Aadi Bioscience's new cancer med Fyarro boasts two firsts: It's the California-based company's first commercial product, and it's the first treatment to take aim at an ultrarare and aggressive form...

Johnson & Johnson COVID-19 Vaccine Fully Approved by Health Canada to Prevent COVID-19 in Individuals 18 years and Older

Vaccine demonstrates protection against COVID-19 related hospitalization and death, and across different variants.

Seqirus Announces U.S. FDA Approval for Multi-Dose Vial Presentation of First-Ever Adjuvanted, Cell-Based Pandemic Influenza Vaccine

Seqirus, a global leader in influenza prevention and a business of CSL Limited (ASX:CSL), today announced that the U.S. Food and Drug Administration (FDA) has granted supplemental approval of a mul...

FDA Approves First Treatment for Common Type of Post-Transplant Infection that is Resistant to Other Drugs

Today, the U.S. Food and Drug Administration approved Livtencity (maribavir) as the first drug for treating adults and pediatric patients (12 years of age and older and weighing at least 35 kilogra...

Isofol Medical AB (publ) receives FDA Fast Track Designation for arfolitixorin in advanced colorectal cancer (mCRC)

Isofol Medical AB (publ) (Nasdaq Stockholm: ISOFOL), announced today that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation (FTD) for the development of the Company's lead...

It's a wrap: Merck collects enough Acceleron shares for $11.5B buyout despite activist investor defiance

Merck & Co. has consumed Acceleron Pharma, clamorous activist investors notwithstanding.

Neurocrine pens $2.6B biobucks pact with Sosei Heptares for next-gen neuro targets

Neurocrine Biosciences and Sosei Heptares, no strangers to major research pacts, are joining forces for a range of early- to midstage neuro assets. ...

Gilead exercises option for three programmes of Arcus Biosciences

Gilead Sciences has exercised its options, under an agreement signed last year, to obtain exclusive ex-US rights to Arcus Biosciences’ three programmes.

NICE recommends Inrebic for rare blood cancer

NICE have issued a final appraisal determination (FAD) recommending the use of Inrebic (fedratinib) on the NHS for the treatment of myelofibrosis, a rare blood cancer affecting the bone marrow and ...

Pharma News, 2021